The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index

Value in Health

Volumn 19, Issue 2, 2016, Pages 153-157

  Heijnsdijk, Eveline A M ^a   Denham, Dwight ^b   De Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BECKMAN COULTER INC   (United States)

Author keywords

cost effectiveness; modeling; PHI; prostate cancer; PSA; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HEALTH INDEX; PROSTATECTOMY; PROTEIN BLOOD LEVEL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; BIOPSY; BLOOD; COMPARATIVE STUDY; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; COST CONTROL; DIGITAL RECTAL EXAMINATION; EARLY CANCER DIAGNOSIS; ECONOMICS; HEALTH CARE COST; HEALTH STATUS; HEALTH STATUS INDICATOR; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; PROSTATIC NEOPLASMS; STATISTICAL MODEL; TIME FACTOR; UNNECESSARY PROCEDURE; UPREGULATION;

AGED; BIOPSY; COMPUTER SIMULATION; COST SAVINGS; COST-BENEFIT ANALYSIS; DIGITAL RECTAL EXAMINATION; EARLY DETECTION OF CANCER; HEALTH CARE COSTS; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; UNNECESSARY PROCEDURES; UP-REGULATION;

EID: 84954289922     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2015.12.002     Document Type: Article

References (25)

1. F.H. Schröder, J. Hugosson, M.J. Roobol, and et al. Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
2. F.H. Schröder, J. Hugosson, M.J. Roobol, and et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up Lancet 384 2014 2027 2035
3. G. Draisma, R. Boer, S.J. Otto, and et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878
4. F.H. Schröder, R.C. van den Bergh, T. Wolters, and et al. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies Eur Urol 57 2010 256 266
5. M.J. Roobol, R. Kranse, C.H. Bangma, and et al. Screening for prostate cancer: results of the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer Eur Urol 64 2013 530 539
6. F.H. Jansen, R.H. van Schaik, J. Kurstjens, and et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 57 2010 921 927
7. W.J. Catalona, G. Bartsch, H.G. Rittenhouse, and et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/mL prostate specific antigen J Urol 171 2004 2239 2244
8. M. Lazzeri, A. Haese, A. de la Taille, and et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/mL: a multicentric European study Eur Urol 63 2013 986 994
9. S. Loeb, M.G. Sanda, D.L. Broyles, and et al. The prostate health index (phi) selectively identifies clinically-significant prostate cancer J Urol 193 2015 1163 1169
10. T. Nordström, A. Vickers, M. Assel, and et al. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer Eur Urol 68 2015 139 146
11. X. Filella, and N. Gimenez Evaluation of [-2] proPSA and prostate health index (phi) for the detection of prostate cancer: a systematic review and meta-analysis Clin Chem Lab Med 51 2013 729 739
12. M.B. Nichol, J. Wu, J. Huang, and et al. Cost-effectiveness of Prostate Health Index for prostate cancer detection BJU Int 110 2012 353 362
13. E.A. Heijnsdijk, T.M. de Carvalho, A. Auvinen, and et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data J Natl Cancer Inst 107 2015 36
14. E.A. Heijnsdijk, A. der Kinderen, E.M. Wever, and et al. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer Br J Cancer 101 2009 1833 1838
15. E.A. Heijnsdijk, E.M. Wever, A. Auvinen, and et al. Quality-of-life effects of prostate-specific antigen screening N Engl J Med 367 2012 595 605
16. Office for National Statistics. European Standard Population. Newport, UK: Office for National Statistics.
17. J. Hugosson, G. Aus, H. Lilja, and et al. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma Cancer 100 2004 1397 1405
18. R.C. van den Bergh, S. Roemeling, M.J. Roobol, and et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly Eur Urol 55 2009 1 8
19. P.C. Albertsen, J.A. Hanley, and J. Fine 20-Year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101
20. A. Bill-Axelson, L. Holmberg, F. Filen, and et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial J Natl Cancer Inst 100 2008 1144 1154
21. W.J. Catalona, A.W. Partin, M.G. Sanda, and et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/mL prostate specific antigen range J Urol 185 2011 1650 1655
22. R. Postma, F.H. Schröder, G.J. van Leenders, and et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - section Rotterdam: a comparison of two rounds of screening Eur Urol 52 2007 89 97
23. S.J. Otto, I.W. van der Cruijsen, M.K. Liem, and et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer Int J Cancer 105 2003 394 399
24. National Institute for Health and Clinical Excellence The Guidelines Manual, January 2009 2009 National Institute for Health and Clinical Excellence London
25. D.U. Ekwueme, L.A. Stroud, and Y. Chen Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies Prev Chronic Dis 4 2007 A100